We expect revenue at INR 81,451 Mn, as the quarter is likely to witness a normalization in the US business following the decline in Lenalidomide sales, which had been a key earnings driver over the last few quarters. The lower contribution from this high-margin product is expected to weigh on overall revenue growth.